The Board of Directors is currently comprised of the CEO and three outside members with expertise in the pharmaceutical and biotechnology industry, IP establishment and protection, and business development. 


John McBride, M.S., M.B.A.

Chairman of the Board

John McBride, M.S., M.B.A., joined Intezyne’s Board of Directors upon the Company’s acquisition of Niiki Pharma, where he was a member of the Board of Directors. He is a 25-year veteran of the biotechnology and pharmaceutical industry and brings extensive experience in business development strategy, identification and evaluation of licensing and product acquisition opportunities, and transactional support. Mr. McBride was the Chief Operating Officer of Gloucester Pharmaceuticals Inc, a venture-backed oncology company that was acquired by Celgene Corp. in 2009 for $640 million. Prior to Gloucester he was the Global Head of Oncology Licensing at Pfizer, Inc./Pharmacia Corporation, where he was responsible for licensing strategy and oncology-related in-licensing, out-licensing and product divestiture transactions. Before Pfizer/Pharmacia, he held Senior Executive business and finance positions at CytoTherapeutics, Phytera, Sparta Pharmaceuticals, US Bioscience, and Eastman Kodak. He has been involved in development and marketing of several anti-cancer drugs, including Camptosar®, Ellence®, Emcyt®, Ethyol®, Hexalen®, Istodax®, Sutent® and Vidaza®. Mr. McBride holds a MS degree in chemical engineering from the University of Wisconsin and an MBA from the Wharton School, University of Pennsylvania.  


David Robb, M.A.

David Robb serves as President and COO Gaston Capital Partners, LLC. He began his career in financial services, first as an economist and asset allocation specialist for First Chicago Investment Advisors, a large pension fund management firm, before becoming an interest rate futures broker and trader for The Chicago Corporation. From Chicago, he returned to his hometown of Charlotte to begin a series of entrepreneurial ventures, first in graphic arts and later in a series of internet technology companies in New York, Charlotte, and Seattle. He served on as a director of the Application Developers Alliance and sits on numerous corporate boards in the Gaston Capital Portfolio. He has extensive experience in real estate development, manufacturing and medical technology.

In addition to his corporate board participation, David has served on many nonprofits, primarily focused on environmental causes and animal welfare. He is the chair of Humane Society of the United States North Carolina State Council, a director of Humane Society Legislative Fund and is a long time director of the North Carolina Zoological Society. He holds a B.A. in Business Management from NC State University and an M.A. in economics from Duke University.


Hooshmand Sheshbaradaran, Ph.D. 

Hooshmand Sheshbaradaran, Ph.D., is a current member of the Board of Directors after serving as Niiki Pharma's Chief Executive Officer. He has spent his career in development and marketing of several cancer drugs, including Camptosar®, Ellence®, Emcyt®, Sutent®, and Vidaza®. Prior to founding Niiki Pharma, Dr. Sheshbaradaran was the head of the US subsidiary of Zeneus Pharma Ltd., a venture-backed oncology company acquired by Cephalon, Inc., for $360 million in 2007. Previously he held senior executive positions including Global Director of Oncology Business Development at Roche and Global Director of Oncology, New Products Marketing, at Pharmacia/Pfizer. Dr. Sheshbaradaran earned his Ph.D. from the Karolinksa Institute and held post-doctoral research positions at Northwestern University.   


Kevin Sill, Ph.D.

Kevin Sill, Ph.D., is the Chief Executive Office, Chief Science Officer, President and co-founder of Intezyne. Dr. Sill completed his Ph.D. and M.S. in polymer science and engineering at the University of Massachusetts and holds a B.S. degree in chemistry from the University of Illinois. In November of 2009, Dr. Sill received the inaugural "Young Innovator of the Year" award from R&D Magazine. He is a co-inventor on 27 issued US patents as well as 61 additional international patents and has authored or co-authored 18 peer-reviewed publications in fields spanning polymer chemistry, polymer physics, nanoparticles, and drug delivery applications. Dr. Sill is a registered US Patent Agent. As a principal investigator, he has received over $2.5M in federal research funding. Dr. Sill, a recognized expert in the field of drug delivery, serves on a NIH review panel for Biomaterials, Delivery, and Nanotechnology.

Glenn Walthall, M.B.A.

Glenn Walthall serves as Gaston Capital's Chief Investment Officer. His career spans twenty-five years as a financial industry consultant (Broadway and Seymour), retail bank executive (First Union Securities and Bank of America), and investment banker.  Prior to joining Gaston Capital, Mr. Walthall co-founded Ware River Advisors, LLC, an investment banking firm where he was responsible for arranging growth equity and debt capital and providing M&A advisory services to lower middle market companies across the United States.  His industry experience covers areas including financial services, business services, light industrial and manufacturing, information technology and healthcare.  Mr. Walthall holds a BA in Business Management and a Masters in Business Administration from Virginia Tech.